Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Children's Oncology Group
University of Florida
Endeavor Biomedicines, Inc.
St. Jude Children's Research Hospital
Emory University
Eli Lilly and Company
Milton S. Hershey Medical Center
Dana-Farber Cancer Institute
Seattle Children's Hospital